SCHEMBL19653404

SCHEMBL19653404

CC1=NN(c2ccccc2)C(=O)/C1=C\c1ccc(-c2ccc(Cl)c(C(=O)O)c2)o1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.88
MEN1 O00255 5/20 0.77
KMT2A Q03164 5/20 0.77
APEX1 P27695 4/20 0.77
KDM4E B2RXH2 3/20 0.77
POLB P06746 3/20 0.77
MAPT P10636 3/20 0.77
TDP1 Q9NUW8 3/20 0.77
RECQL P46063 2/20 0.77
THRB P10828 1/20 0.77
PTPN1 P18031 1/20 0.76
XPA P23025 13/20 0.75
NTSR1 P30989 1/20 0.72
GALK1 P51570 1/20 0.72
ALDH1A1 P00352 2/20 0.67
RAB9A P51151 1/20 0.67
GAA P10253 1/20 0.67
PKM P14618 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
CTDSP1 Q9GZU7 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19652479 0.93 MEN1 (0.88) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL20840289 0.93 MEN1 (0.90) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL20840288 0.93 MEN1 (0.90) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL19644261 0.92 EP300 (0.87) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL14426455 0.92 EP300 (0.87) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL20840316 0.92 EP300 (0.87) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL4739884 0.90 EP300 (0.73) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL19644383 0.87 MEN1 (0.88) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL19644384 0.87 MEN1 (0.88) EP300MEN1KMT2AAPEX1KDM4E
SCHEMBL19644529 0.87 XPA (0.88) EP300MEN1KMT2AAPEX1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089577-A1 KU INHIBITORS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2022-03-24 US disclosed
US-11207296-B2 XPA inhibitor compounds and their use INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2021-12-28 US disclosed
US-20200308154-A1 KU INHIBITORS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-10-01 US disclosed
US-20200222367-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-07-16 US disclosed
WO-2017205503-A1 KU INHIBITORS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2017-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089577-A1 KU INHIBITORS AND THEIR USE ZFR, XRCC6, ZFX EP300 771/4885MEN1 2172/4885KMT2A 317/4885
US-20200222367-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE XPOT, XPA, ERCC4 EP300 1218/4885MEN1 884/4885KMT2A 1736/4885
US-11207296-B2 XPA inhibitor compounds and their use XPOT, XPA, ERCC4 EP300 1218/4885MEN1 884/4885KMT2A 1736/4885
US-20200308154-A1 KU INHIBITORS AND THEIR USE ZFR, XRCC6, ZFX EP300 771/4885MEN1 2172/4885KMT2A 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.